Radiation Therapy News and Research

RSS

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.

Resonant Medical to display the next generation of software for its Clarity System

Resonant Medical, an innovator in 3D soft tissue planning, image-guidance and adaptive radiotherapy products, headquartered in Montreal, Canada, today announced that the Company is exhibiting the next generation of software for its Clarity System at the 51st annual American Society of Radiation Oncology (ASTRO) Annual Meeting taking place November 1-5, 2009 in Chicago.

27 Oct 2009

New significant tool to improve the quality of care for patients with brain tumors released

While the nation is debating how best to reform healthcare, the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) announce a new significant tool to improve the quality of care for patients who suffer from brain tumors.

27 Oct 2009

BioMarin Pharmaceutical announces the acquisition of Huxley Pharmaceuticals

BioMarin Pharmaceutical Inc. announced today that it has acquired Huxley Pharmaceuticals, Inc. (Huxley), which has rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).

27 Oct 2009

Results from Phase I dose-escalation study of AT-101 announced

Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23, 2009; Abstract # 449).

26 Oct 2009

Elekta to demonstrate stereotactic solutions at the 2009 CNS Annual Meeting

At the 2009 Congress of Neurological Surgeons (CNS) Annual Meeting, October 24-28 in New Orleans, Louisiana, Elekta will demonstrate how its line of stereotactic solutions expand treatment capabilities and bring new hope for patients presenting serious conditions.

From Elekta 24 Oct 2009

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company’s Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.

23 Oct 2009

AEOL 10150 increases regeneration of GI stem cells: NIAID study results

Aeolus Pharmaceuticals, Inc. announced today that recent experiments in preclinical models conducted by the National Institutes of Health’s (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasure Development program have shown that AEOL 10150 can effectively increase regeneration of gastro-intestinal (GI) stem cells, reduce the severity and duration of diarrhea and improve survival when administered at 24 hours after doses of total-body irradiation that produce the lethal GI syndrome.

23 Oct 2009

TomoTherapy adds the TomoHD treatment system to its suite of advanced radiation therapy solutions

TomoTherapy Incorporated today announced that it has extended its suite of advanced radiation therapy solutions with the addition of the TomoHD™ treatment system, an efficient, all-purpose new system designed to make it easier for any radiation oncology department to adopt TomoTherapy® technology for its patient population.

22 Oct 2009

Northwest Biotherapeutics announces long-term data from Phase I and Phase I/II clinical trials of DCVax-Brain

Northwest Biotherapeutics, Inc. today announced further long-term follow-up data, for the period from January through September 2009, from its prior Phase I and Phase I/II clinical trials conducted at UCLA with DCVax®-Brain in patients with Glioblastoma multiforme ("GBM"). GBM is the most rapid and lethal type of brain cancer. During the update period, only one of the twenty patients treated with DCVax®-Brain (in addition to standard of care) died, and that patient had survived for nearly 7 years (80.5 months).

21 Oct 2009

Celsion completes patient enrollment in its global Phase III ThermoDox trial

Celsion Corporation announced today that it has completed a critical regulatory step in the countries of China and Japan to rapidly enroll patients in its global Phase III ThermoDox trial for the treatment of Hepatocellular Carcinoma (HCC), also known as primary liver cancer.

21 Oct 2009

Oxygen Biotherapeutics announces its expanded product development plan

Oxygen Biotherapeutics, Inc. announced its expanded product development plan.

21 Oct 2009

CMS requested for coverage of two FDG PET scans during the initial treatment

Seven medical imaging groups wrote a joint letter to the Centers for Medicare and Medicaid Services (CMS) to formally request coverage of two fluorodeoxyglucose (FDG) positron emission tomography (PET) scans for a patient during the initial treatment evaluation. Currently, CMS covers only one FDG-PET study during initial treatment-a limitation that the groups believe is contrary to good clinical practice under certain circumstances.

20 Oct 2009

Philippines and Malaysian regulatory agencies approve Celsion’s Phase III Thermodox trial

Celsion Corporation announced today that it has received approval from the regulatory agencis in the Philippines and Malaysia for its Pivotal Phase III primary liver cancer Clinical Trial Application.

19 Oct 2009

Lubricin injections can reduce cartilage degeneration

Medical researchers will report findings today (Oct. 19) that demonstrate that injecting the protein lubricin into knee joints can dramatically reduce cartilage degeneration.

19 Oct 2009

Physical therapists can promote early diagnosis of breast cancer-related lymphedema

As breast cancer awareness month is observed during October, the American Physical Therapy Association (APTA) is hoping to shine a spotlight on lymphedema, a chronic, debilitating and often irreversible side effect of cancer treatment.

19 Oct 2009

Institute Curie Hospital in France adds another TomoTherapy radiation therapy system

TomoTherapy Incorporated announced today that the Institute Curie Hospital in France has purchased a second TomoTherapy® radiation therapy system, to support the increasing demand for intensity-modulated radiation therapy (IMRT). The Institute Curie Hospital has been treating cancer patients with TomoTherapy technology since March 2007, when it became the first hospital in France to adopt the technology.

19 Oct 2009

Genes to determine which rectal cancer patient can avoid surgical procedure for treatment

A set of 87 genes one day may be used to routinely determine which patients can be successfully treated for advanced rectal cancer without undergoing a surgical procedure, researchers announced at the 2009 Clinical Congress of the American College of Surgeons.

15 Oct 2009

NICoE to study how brain works after sustaining combat-related injury using Elekta Neuromag

Projected to open in mid 2010, the National Intrepid Center of Excellence (NICoE) is a facility dedicated to the study and care of military personnel and veterans suffering from traumatic brain injury (TBI) and psychological health issues. Using Elekta Neuromag®, an advanced magnetoencephalography (MEG) device, NICoE plans to shed light on how the brain works after sustaining combat-related injury.

From Elekta 15 Oct 2009

New relocatable radiation therapy system from TomoTherapy

TomoTherapy Incorporated announced today the availability of the industry's first relocatable radiation therapy solution -- TomoMobile™ -- which is designed to quickly and cost-effectively bring cutting-edge radiation therapy solutions to patients in underserved and rural markets.

15 Oct 2009

Xoft to showcase a variety of investigational IORT oncology applications at ACS Annual Congress

Clinical experience with the FDA cleared Axxent® Electronic Brachytherapy, eBx(TM), System from Xoft shows promise for the multi-disciplinary use of the isotope-free cancer treatment platform to deliver intraoperative radiation therapy (IORT). Xoft will showcase a variety of investigational IORT oncology applications at the American College of Surgeons 95th Annual Clinical Congress here in Chicago, October 11-15, 2009.

12 Oct 2009

Radiation Therapy News and Research

Further Reading

Resonant Medical to display the next generation of software for its Clarity System

New significant tool to improve the quality of care for patients with brain tumors released

BioMarin Pharmaceutical announces the acquisition of Huxley Pharmaceuticals

Results from Phase I dose-escalation study of AT-101 announced

Elekta to demonstrate stereotactic solutions at the 2009 CNS Annual Meeting

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

AEOL 10150 increases regeneration of GI stem cells: NIAID study results

TomoTherapy adds the TomoHD treatment system to its suite of advanced radiation therapy solutions

Northwest Biotherapeutics announces long-term data from Phase I and Phase I/II clinical trials of DCVax-Brain

Celsion completes patient enrollment in its global Phase III ThermoDox trial

Oxygen Biotherapeutics announces its expanded product development plan

CMS requested for coverage of two FDG PET scans during the initial treatment

Philippines and Malaysian regulatory agencies approve Celsion’s Phase III Thermodox trial

Lubricin injections can reduce cartilage degeneration

Physical therapists can promote early diagnosis of breast cancer-related lymphedema

Institute Curie Hospital in France adds another TomoTherapy radiation therapy system

Genes to determine which rectal cancer patient can avoid surgical procedure for treatment

NICoE to study how brain works after sustaining combat-related injury using Elekta Neuromag

New relocatable radiation therapy system from TomoTherapy

Xoft to showcase a variety of investigational IORT oncology applications at ACS Annual Congress

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News